Ligand validation:3GUH

PE3: 3,6,9,12,15,18,21,24,27,30,33,36,39-TRIDECAOXAHENTETRACONTANE-1,41-DIOL

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
3GUH_PE3_A_491	17%	55%	0.178	0.887	0.83	0.92	-	-	1	0	26%	0.2558
3GUH_PE3_A_489	9%	62%	0.364	0.888	0.74	0.71	-	-	6	0	86%	0.7558
2R4T_PE3_A_513	18%	82%	0.143	0.894	0.48	0.33	-	-	0	0	7%	6.98
9INR_PE3_B_202	61%	39%	0.106	0.902	0.95	1.4	-	7	8	0	95%	0.4767
4Y5D_PE3_A_201	34%	36%	0.135	0.879	1.15	1.36	2	5	15	0	65%	0.6512
2VFX_PE3_C_1210	32%	71%	0.107	0.916	0.5	0.6	-	-	0	0	23%	0.2326
5DHD_PE3_A_808	30%	71%	0.095	0.916	0.43	0.67	-	-	2	0	12%	11.63
6MGJ_PE3_D_802	29%	62%	0.133	0.917	0.56	0.88	-	-	0	0	30%	0.3023

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.